Stockscreener 앱 받기
70.07
0.07%
-0.05
시간 외 거래:
70.13
0.06
+0.09%
전일 마감가:
$70.12
열려 있는:
$69.61
하루 거래량:
1.13M
Relative Volume:
0.41
시가총액:
$13.58B
수익:
$502.08M
순이익/손실:
$-732.94M
주가수익비율:
-18.52
EPS:
-3.7842
순현금흐름:
$-455.50M
1주 성능:
+3.07%
1개월 성능:
-0.92%
6개월 성능:
+33.80%
1년 성능:
+107.61%
1일 변동 폭
$68.25
$70.70
1주일 범위
$67.73
$71.98
52주 변동 폭
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
70.07 | 13.59B | 502.08M | -732.94M | -455.50M | -3.7842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | William Blair | Outperform |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-11 | 개시 | Bernstein | Outperform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio Pharma launches initiative to define age-specific pathways for FGFR3 testing - Traders Union
Mizuho raises BridgeBio Pharma stock price target on drug strength By Investing.com - Investing.com Canada
Mizuho Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
BBIO: Mizuho Raises Price Target to $106, Maintains 'Outperform' Rating | BBIO Stock News - GuruFocus
Raymond James Maintains BridgeBio Pharma (BBIO) Outperform Recommendation - MSN
Aug Sectors: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARMarket Performance Summary & Entry Point Strategy Guides - baoquankhu1.vn
Resistance Check: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEAR2026 Trade Ideas & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
BBIO PE Ratio & Valuation, Is BBIO Overvalued - Intellectia AI
(BBIO) Risk Channels and Responsive Allocation - Stock Traders Daily
Fred Alger Management LLC Has $10.25 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma CEO Kumar Neil sells $5.5m in BBIO stock - Investing.com Nigeria
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat
BridgeBio (BBIO) CEO’s family trusts sell 80,000 company shares - Stock Titan
HighVista Strategies LLC Raises Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Granahan Investment Management LLC Buys 78,588 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Farallon Capital Management LLC Has $425.49 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback - Yahoo Finance
The week in pharma: action, reaction and insight – week to March 13, 2026 - The Pharma Letter
Boone Capital Management LLC Buys Shares of 460,282 BridgeBio Pharma, Inc. $BBIO - MarketBeat
Prosight Management LP Sells 208,187 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BBIO6336503 Bond Risk Analysis - TradingView
BBIO6336503 Bond Coupon Analysis — Rate & Payments - TradingView
How Positive Phase 3 LGMD Data Could Shape BridgeBio Pharma’s (BBIO) Risk Profile and Upside Potential - simplywall.st
Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Tenet Healthcare (THC) - The Globe and Mail
BridgeBio Touts Attruby Uptake, Bayer's Europe Rollout, and Pipeline Timelines - National Today
BridgeBio Pharma Touts Attruby Uptake, Bayer’s Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf - MarketBeat
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - MarketBeat
BridgeBio Looks At Genetic Testing To Build Out BBP-418 Launch In LGMD2I/R9 - Citeline News & Insights
BridgeBio Pharma Director Sells Shares - TradingView
BridgeBio director sells 8,671 shares after option exercise | BBIO SEC FilingForm 4 - Stock Titan
BridgeBio (BBIO) soars 13% on double-digit price target upgrade - MSN
A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - simplywall.st
BridgeBio reports Phase III progress for BBP-418 - The Pharma Letter
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga
Barclays Maintains Overweight on BridgeBio Pharma (BBIO) March 2026 - Meyka
Capital Research Global Investors Sells 2,055,172 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Leerink Maintains Outperform on BBIO, BridgeBio Pharma, Inc. March 12, 2026 - Meyka
BridgeBio (BBIO) Reports Promising Phase 3 Data for BBP-418 in M - GuruFocus
BridgeBio Pharma Presents Promising Phase 3 FORTIFY Interim Analysis Results for BBP-418 in LGMD2I/R9 at MDA Conference - Quiver Quantitative
BridgeBio Pharma plans to submit NDA for BBP-418 to FDA in H1 2026 - marketscreener.com
Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026 - TradingView
LGMD trial drug lets people finish 100m test 31s faster than placebo - Stock Titan
BridgeBio (BBIO) Reports Wider Q4 Loss of $1/Share vs $0.63 Estimate; Stock Surges 13% - AlphaStreet
HC Wainwright Raises Earnings Estimates for BridgeBio Pharma - MarketBeat
BridgeBio (BBIO) Sees Price Target Boost and Earns Overweight Ra - GuruFocus
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade - Insider Monkey
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
U.S. Indexes Finished Mixed Tuesday As BridgeBio Pharma Led, Centene Lagged - Barron's
Valantine plans option-based sale; prior 25,484 shares sold (BBIO) - Stock Titan
Barclays reiterates Overweight on BridgeBio Pharma stock By Investing.com - Investing.com Canada
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):